CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Marco Falasca

OPENALEX: A5089714768↗ORCID: 0000-0002-9801-7235↗

Affiliations

Organizations

Curtin Universityauthorship · AU

Public evidence

4 connected articles

Enhancing Tetrahydrocannabinol's Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011.2025 · Europe PMC Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.2025 · Europe PMC Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases.2023 · Europe PMC Cannabinoids and Cancer.2021 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Marco Falasca - Medical Cannabis Research Engine